GlassScriptPhysician profile
Sonia C Simoes
NPI 1346406600
$3,263.00
in general payments reported to CMS, 2019-2025
24 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $325 · 2021: $550 · 2022: $625 · 2023: $612 · 2024: $287 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403 · Education: $13.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,403.48 |
| Education | $13.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $552.66 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $493.66 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $291.23 | 2021-2025 | |
| Novo Nordisk INC | $281.62 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.41 | 2019-2025 | Jardiance |
| Ardelyx, INC. | $172.08 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $153.37 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $131.87 | 2019 | |
| Horizon Therapeutics Plc | $124.17 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $109.31 | 2020-2023 | Acthar |
| Amgen INC. | $100.92 | 2021-2025 | Krystexxa, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $100.76 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $92.68 | 2019-2023 | Rayaldee |
| Merck Sharp & Dohme LLC | $89.54 | 2020-2023 | Verquvo, Steglatro |
| Aurinia Pharma U.S., INC. | $74.16 | 2022-2023 | Lupkynis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $71.62 | 2023 | |
| Lilly USA, LLC | $68.46 | 2020-2022 | |
| Calliditas Therapeutics US INC. | $43.12 | 2024-2025 | Tarpeyo |
| Akebia Therapeutics INC | $41.85 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $35.96 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $17.62 | 2024 | Renal - Pd |
| Glaxosmithkline, LLC. | $14.33 | 2021 | |
| Hikma Pharmaceuticals USA | $13.72 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Simoes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.